Efficacy, safety and tolerability of oral semaglutide vs placebo added to insulin ± metformin in patients with type 2 diabetes: The PIONEER 8 Trial
Diabetes Care Sep 25, 2019
Zinman B, Aroda VR, Buse JB, et al. - In this investigation involving patients with T2D, researchers tested the effectiveness, safety and tolerability of oral semaglutide added to insulin ± metformin. Study participants were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181), or placebo (N = 184) in a 52-week, double-blind trial. If added to insulin ± metformin in patients with T2D, oral semaglutide was superior to placebo in reducing HbA1c and body weight. Other glucagon-like peptide-1 receptor agonists complied with the safety profile. Nausea was the most frequent adverse event with oral semaglutide.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries